DD272077A5 - Verfahren zur herstellung von piperazinyl-heterocyclischen verbindungen - Google Patents

Verfahren zur herstellung von piperazinyl-heterocyclischen verbindungen Download PDF

Info

Publication number: DD272077A5
Authority: DD; German Democratic Republic
Prior art keywords: mmol; ethyl acetate; piperazinyl; evaporated; ethyl
Prior art date: 1987-03-02

Application number

DD88313286A

Other languages

German (de)

English (en)

Inventor

Iii John A Lowe

Arthur A Nagel

Original Assignee

��@��Kk��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-03-02

Filing date

1988-03-01

Publication date

1989-09-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22202301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD272077(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1988-03-01 Application filed by ��@��Kk�� filed Critical ��@��Kk��

1989-09-27 Publication of DD272077A5 publication Critical patent/DD272077A5/de

Links

238000004519 manufacturing process Methods 0.000 title description 2
238000000034 method Methods 0.000 claims abstract description 17
239000002253 acid Substances 0.000 claims abstract description 11
150000003839 salts Chemical class 0.000 claims abstract description 9
-1 nitro, quinolyl Chemical group 0.000 claims description 47
150000001875 compounds Chemical class 0.000 claims description 40
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
239000000460 chlorine Substances 0.000 claims description 9
229910052731 fluorine Inorganic materials 0.000 claims description 9
125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 8
125000001153 fluoro group Chemical group F* 0.000 claims description 8
PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 claims description 7
229910052801 chlorine Inorganic materials 0.000 claims description 7
JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 claims description 7
125000001309 chloro group Chemical group Cl* 0.000 claims description 6
125000001624 naphthyl group Chemical group 0.000 claims description 6
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
239000011737 fluorine Substances 0.000 claims description 5
125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 claims description 5
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 4
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
125000004093 cyano group Chemical group *C#N 0.000 claims description 4
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 4
125000001041 indolyl group Chemical group 0.000 claims description 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
150000004885 piperazines Chemical class 0.000 claims description 3
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
AYVGBNGTBQLJBG-UHFFFAOYSA-N [3-(hydroxymethyl)cyclopentyl]methanol Chemical compound OCC1CCC(CO)C1 AYVGBNGTBQLJBG-UHFFFAOYSA-N 0.000 claims description 2
125000005874 benzothiadiazolyl group Chemical group 0.000 claims description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
229910052740 iodine Inorganic materials 0.000 claims description 2
239000011630 iodine Substances 0.000 claims description 2
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 2
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
125000005493 quinolyl group Chemical group 0.000 claims description 2
125000003003 spiro group Chemical group 0.000 claims description 2
125000005956 isoquinolyl group Chemical group 0.000 claims 1
208000028017 Psychotic disease Diseases 0.000 abstract description 7
238000002360 preparation method Methods 0.000 abstract description 5
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract description 3
239000013543 active substance Substances 0.000 abstract description 2
150000002391 heterocyclic compounds Chemical class 0.000 abstract description 2
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 174
238000010992 reflux Methods 0.000 description 48
239000007787 solid Substances 0.000 description 46
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 44
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 42
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 38
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 38
239000011541 reaction mixture Substances 0.000 description 37
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 34
229910000041 hydrogen chloride Inorganic materials 0.000 description 34
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 20
239000000047 product Substances 0.000 description 19
229910000029 sodium carbonate Inorganic materials 0.000 description 19
ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical group C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 17
239000012071 phase Substances 0.000 description 17
239000000203 mixture Substances 0.000 description 16
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
238000004458 analytical method Methods 0.000 description 14
239000012267 brine Substances 0.000 description 14
239000000741 silica gel Substances 0.000 description 14
229910002027 silica gel Inorganic materials 0.000 description 14
235000009518 sodium iodide Nutrition 0.000 description 14
229910052938 sodium sulfate Inorganic materials 0.000 description 14
235000011152 sodium sulphate Nutrition 0.000 description 14
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
229920006395 saturated elastomer Polymers 0.000 description 13
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
239000007789 gas Substances 0.000 description 12
238000003756 stirring Methods 0.000 description 11
CPLWKJWNQCWKQV-UHFFFAOYSA-N 6-(2-bromoethyl)-3h-1,3-benzoxazol-2-one Chemical compound BrCCC1=CC=C2NC(=O)OC2=C1 CPLWKJWNQCWKQV-UHFFFAOYSA-N 0.000 description 10
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 10
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 9
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
239000000243 solution Substances 0.000 description 8
239000000725 suspension Substances 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
241000400611 Eucalyptus deanei Species 0.000 description 6
239000003480 eluent Substances 0.000 description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
229960004592 isopropanol Drugs 0.000 description 6
VNICFCQJUVFULD-UHFFFAOYSA-N 1-(1-naphthalenyl)piperazine Chemical compound C1CNCCN1C1=CC=CC2=CC=CC=C12 VNICFCQJUVFULD-UHFFFAOYSA-N 0.000 description 5
239000008346 aqueous phase Substances 0.000 description 5
MKYNHKOAYQRSBD-UHFFFAOYSA-N dioxouranium;nitric acid Chemical compound O=[U]=O.O[N+]([O-])=O.O[N+]([O-])=O MKYNHKOAYQRSBD-UHFFFAOYSA-N 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
230000003197 catalytic effect Effects 0.000 description 4
125000005999 2-bromoethyl group Chemical group 0.000 description 3
WXJWBEAGVWVEDM-UHFFFAOYSA-N 5-(2-chloroacetyl)-1,3-dihydroindol-2-one Chemical compound ClCC(=O)C1=CC=C2NC(=O)CC2=C1 WXJWBEAGVWVEDM-UHFFFAOYSA-N 0.000 description 3
HPXJIGZLXHQSGU-UHFFFAOYSA-N 5-(2-chloroethyl)-1,3-dihydroindol-2-one Chemical compound ClCCC1=CC=C2NC(=O)CC2=C1 HPXJIGZLXHQSGU-UHFFFAOYSA-N 0.000 description 3
QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
KRDOFMHJLWKXIU-UHFFFAOYSA-N ID11614 Chemical compound C1CNCCN1C1=NSC2=CC=CC=C12 KRDOFMHJLWKXIU-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
230000000701 neuroleptic effect Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
229920000137 polyphosphoric acid Polymers 0.000 description 3
239000002904 solvent Substances 0.000 description 3
KOOKQPMRBFPCJH-UHFFFAOYSA-N 1-benzyl-4-(6-fluoronaphthalen-1-yl)piperazine Chemical compound C=1C=CC2=CC(F)=CC=C2C=1N(CC1)CCN1CC1=CC=CC=C1 KOOKQPMRBFPCJH-UHFFFAOYSA-N 0.000 description 2
125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 2
YIDMPLFTBQMVAQ-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)-2,1,3-benzothiadiazole Chemical compound C1CN(C)CCN1C1=CC=CC2=NSN=C12 YIDMPLFTBQMVAQ-UHFFFAOYSA-N 0.000 description 2
JZJFRQGXFVVZPK-UHFFFAOYSA-N 4-piperazin-1-yl-2,1,3-benzothiadiazole Chemical compound C1CNCCN1C1=CC=CC2=NSN=C12 JZJFRQGXFVVZPK-UHFFFAOYSA-N 0.000 description 2
OLHPDERTOIKVER-UHFFFAOYSA-N 5-[2-(4-naphthalen-1-ylpiperazin-1-yl)ethyl]benzimidazol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=CC4=NC(N=C4C=3)=O)=CC=CC2=C1 OLHPDERTOIKVER-UHFFFAOYSA-N 0.000 description 2
LTKOVYPSNBPPDB-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(NC4=CC=3)=O)=NSC2=C1 LTKOVYPSNBPPDB-UHFFFAOYSA-N 0.000 description 2
IMMWCMHVIKCYSW-UHFFFAOYSA-N 6-(4-bromobutanoyl)-3h-1,3-benzoxazol-2-one Chemical compound BrCCCC(=O)C1=CC=C2NC(=O)OC2=C1 IMMWCMHVIKCYSW-UHFFFAOYSA-N 0.000 description 2
AEJRZACCYFBKJC-UHFFFAOYSA-N 6-(4-hydroxybutyl)-3h-1,3-benzoxazol-2-one Chemical compound OCCCCC1=CC=C2NC(=O)OC2=C1 AEJRZACCYFBKJC-UHFFFAOYSA-N 0.000 description 2
PZLGBASBFOSOOX-UHFFFAOYSA-N 6-[2-(4-phthalazin-1-ylpiperazin-1-yl)ethyl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(OC4=C3)=O)=NN=CC2=C1 PZLGBASBFOSOOX-UHFFFAOYSA-N 0.000 description 2
ZWSBCAMYZMCUFX-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(OC4=C3)=O)=NSC2=C1 ZWSBCAMYZMCUFX-UHFFFAOYSA-N 0.000 description 2
OUOBVBYOAFEOKS-UHFFFAOYSA-N 6-fluoronaphthalen-1-amine Chemical compound FC1=CC=C2C(N)=CC=CC2=C1 OUOBVBYOAFEOKS-UHFFFAOYSA-N 0.000 description 2
PRGBEFGWVMWEGQ-UHFFFAOYSA-N 6-fluoronaphthalene-1-carboxylic acid Chemical compound FC1=CC=C2C(C(=O)O)=CC=CC2=C1 PRGBEFGWVMWEGQ-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 2
239000013078 crystal Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
QOYUUAUHYUIMDO-UHFFFAOYSA-N ethenyl 4-(2,1,3-benzothiadiazol-4-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC=C)CCN1C1=CC=CC2=NSN=C12 QOYUUAUHYUIMDO-UHFFFAOYSA-N 0.000 description 2
WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000006260 foam Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
125000002346 iodo group Chemical group I* 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
125000004193 piperazinyl group Chemical group 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
CRVNOUFSHGQXRN-UHFFFAOYSA-N 1,3-dihydroindol-2-one hydrate hydrochloride Chemical compound O.Cl.C1=CC=C2NC(=O)CC2=C1 CRVNOUFSHGQXRN-UHFFFAOYSA-N 0.000 description 1
LWPVQTZPRWKELS-UHFFFAOYSA-N 1-(4-methoxynaphthalen-1-yl)piperazine Chemical compound C12=CC=CC=C2C(OC)=CC=C1N1CCNCC1 LWPVQTZPRWKELS-UHFFFAOYSA-N 0.000 description 1
FBPPFIPXMJEJCU-UHFFFAOYSA-N 1-(5,6,7,8-tetrahydronaphthalen-1-yl)piperazine Chemical compound C1CCCC2=C1C=CC=C2N1CCNCC1 FBPPFIPXMJEJCU-UHFFFAOYSA-N 0.000 description 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
DZWBPVWZCQJMGW-UHFFFAOYSA-N 1-piperazin-1-ylphthalazine Chemical compound C1CNCCN1C1=NN=CC2=CC=CC=C12 DZWBPVWZCQJMGW-UHFFFAOYSA-N 0.000 description 1
DRLGIZIAMHIQHL-UHFFFAOYSA-N 2,1,3-benzothiadiazol-4-amine Chemical compound NC1=CC=CC2=NSN=C12 DRLGIZIAMHIQHL-UHFFFAOYSA-N 0.000 description 1
SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
GRHQDJDRGZFIPO-UHFFFAOYSA-N 4-bromobutanoic acid Chemical compound OC(=O)CCCBr GRHQDJDRGZFIPO-UHFFFAOYSA-N 0.000 description 1
KLTHGJYCURVMAK-UHFFFAOYSA-N 4-piperazin-1-ylquinazoline Chemical compound C1CNCCN1C1=NC=NC2=CC=CC=C12 KLTHGJYCURVMAK-UHFFFAOYSA-N 0.000 description 1
PVABLRWKKBXIDZ-UHFFFAOYSA-N 5-(2-bromoethyl)benzimidazol-2-one Chemical compound C1=C(CCBr)C=CC2=NC(=O)N=C21 PVABLRWKKBXIDZ-UHFFFAOYSA-N 0.000 description 1
OQBRVZPKULURAO-UHFFFAOYSA-N 5-(2-chloroacetyl)-1,3,3-trimethylindol-2-one Chemical compound ClCC(=O)C1=CC=C2N(C)C(=O)C(C)(C)C2=C1 OQBRVZPKULURAO-UHFFFAOYSA-N 0.000 description 1
JNXCWOWVMUDGSV-UHFFFAOYSA-N 5-(2-chloroacetyl)-1-(3-chlorophenyl)-3h-indol-2-one Chemical compound O=C1CC2=CC(C(=O)CCl)=CC=C2N1C1=CC=CC(Cl)=C1 JNXCWOWVMUDGSV-UHFFFAOYSA-N 0.000 description 1
GCULOOUUFWFQNZ-UHFFFAOYSA-N 5-(2-chloroacetyl)-1-ethyl-3h-indol-2-one Chemical compound ClCC(=O)C1=CC=C2N(CC)C(=O)CC2=C1 GCULOOUUFWFQNZ-UHFFFAOYSA-N 0.000 description 1
RRFQHTVONYSCEQ-UHFFFAOYSA-N 5-(2-chloroacetyl)-1-methyl-3h-indol-2-one Chemical compound ClCC(=O)C1=CC=C2N(C)C(=O)CC2=C1 RRFQHTVONYSCEQ-UHFFFAOYSA-N 0.000 description 1
JGGIQZREXCXUJM-UHFFFAOYSA-N 5-(2-chloroethyl)-1,3,3-trimethylindol-2-one Chemical compound ClCCC1=CC=C2N(C)C(=O)C(C)(C)C2=C1 JGGIQZREXCXUJM-UHFFFAOYSA-N 0.000 description 1
ASDZHNQIEBDPTE-UHFFFAOYSA-N 5-(2-chloroethyl)-1,3-dimethyl-3h-indol-2-one Chemical compound C1=C(CCCl)C=C2C(C)C(=O)N(C)C2=C1 ASDZHNQIEBDPTE-UHFFFAOYSA-N 0.000 description 1
WKEZOIZTNJYCOJ-UHFFFAOYSA-N 5-(2-chloroethyl)-1-ethyl-3h-indol-2-one Chemical compound ClCCC1=CC=C2N(CC)C(=O)CC2=C1 WKEZOIZTNJYCOJ-UHFFFAOYSA-N 0.000 description 1
XRLXFMZCUVDADB-UHFFFAOYSA-N 5-(2-chloroethyl)-1-methyl-3h-indol-2-one Chemical compound ClCCC1=CC=C2N(C)C(=O)CC2=C1 XRLXFMZCUVDADB-UHFFFAOYSA-N 0.000 description 1
LYLJGWHKMPQQDA-UHFFFAOYSA-N 5-(2-chloroethyl)-6-fluoro-1,3-dihydroindol-2-one Chemical compound C1=C(CCCl)C(F)=CC2=C1CC(=O)N2 LYLJGWHKMPQQDA-UHFFFAOYSA-N 0.000 description 1
BTHUDFYOBJFKRQ-UHFFFAOYSA-N 5-(2-chloroethyl)-7-fluoro-1,3-dihydroindol-2-one Chemical compound FC1=CC(CCCl)=CC2=C1NC(=O)C2 BTHUDFYOBJFKRQ-UHFFFAOYSA-N 0.000 description 1
DQWSDBRELVFKGC-UHFFFAOYSA-N 5-(4-chlorobutyl)-1-ethyl-3h-indol-2-one Chemical compound ClCCCCC1=CC=C2N(CC)C(=O)CC2=C1 DQWSDBRELVFKGC-UHFFFAOYSA-N 0.000 description 1
DKZVMJZADWLCEK-UHFFFAOYSA-N 5-(4-chlorobutyl)-7-fluoro-1,3-dihydroindol-2-one Chemical compound FC1=CC(CCCCCl)=CC2=C1NC(=O)C2 DKZVMJZADWLCEK-UHFFFAOYSA-N 0.000 description 1
GEJKYGSJUJTWOZ-UHFFFAOYSA-N 5-[2-(4-naphthalen-1-ylpiperazin-1-yl)ethyl]-1,3-dihydroindol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(NC4=CC=3)=O)=CC=CC2=C1 GEJKYGSJUJTWOZ-UHFFFAOYSA-N 0.000 description 1
ACEOJRSDTUJZPF-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,3,3-trimethylindol-2-one hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)C(=O)N(C4=CC=3)C)=NSC2=C1 ACEOJRSDTUJZPF-UHFFFAOYSA-N 0.000 description 1
SUFDLVMUGIVQLD-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,3-dimethyl-3h-indol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(C)C(=O)C(C4=C3)C)=NSC2=C1 SUFDLVMUGIVQLD-UHFFFAOYSA-N 0.000 description 1
NCYBUBNVBAHNLA-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-3h-indol-2-one;hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(=O)N(C4=CC=3)CC)=NSC2=C1 NCYBUBNVBAHNLA-UHFFFAOYSA-N 0.000 description 1
AHXHIRWJGGSOTN-UHFFFAOYSA-N 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-7-fluoro-1,3-dihydroindol-2-one;hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC=3C=C(C=4NC(=O)CC=4C=3)F)=NSC2=C1 AHXHIRWJGGSOTN-UHFFFAOYSA-N 0.000 description 1
MDZXAGFVGOSIBG-UHFFFAOYSA-N 5-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-1-ethyl-3h-indol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCC=3C=C4CC(=O)N(C4=CC=3)CC)=NSC2=C1 MDZXAGFVGOSIBG-UHFFFAOYSA-N 0.000 description 1
LBIBISGMTJJFKQ-UHFFFAOYSA-N 5-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-7-fluoro-1,3-dihydroindol-2-one;hydrate Chemical compound O.C1=CC=C2C(N3CCN(CC3)CCCCC=3C=C(C=4NC(=O)CC=4C=3)F)=NSC2=C1 LBIBISGMTJJFKQ-UHFFFAOYSA-N 0.000 description 1
KWJYLSMUUIXRBO-UHFFFAOYSA-N 6-(2-bromoethyl)-1,3-benzothiazole 1-oxide Chemical compound BrCCC1=CC=C2N=CS(=O)C2=C1 KWJYLSMUUIXRBO-UHFFFAOYSA-N 0.000 description 1
CYVQZXCJZRDKLT-UHFFFAOYSA-N 6-(4-chlorobutyl)-3h-1,3-benzoxazol-2-one Chemical compound ClCCCCC1=CC=C2NC(=O)OC2=C1 CYVQZXCJZRDKLT-UHFFFAOYSA-N 0.000 description 1
FTRXDTCNQDGOEU-UHFFFAOYSA-N 6-[2-(4-quinazolin-4-ylpiperazin-1-yl)ethyl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(OC4=C3)=O)=NC=NC2=C1 FTRXDTCNQDGOEU-UHFFFAOYSA-N 0.000 description 1
XVWLLSAJVOZBEN-UHFFFAOYSA-N 6-[2-(4-quinolin-8-ylpiperazin-1-yl)ethyl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CN=C2C(N3CCN(CC3)CCC3=CC=C4NC(OC4=C3)=O)=CC=CC2=C1 XVWLLSAJVOZBEN-UHFFFAOYSA-N 0.000 description 1
ZZVDGMSWFXVSLJ-UHFFFAOYSA-N 6-[2-[4-(4-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl]-3h-1,3-benzoxazol-2-one Chemical compound C12=CC=CC=C2C(OC)=CC=C1N1CCN(CCC=2C=C3OC(=O)NC3=CC=2)CC1 ZZVDGMSWFXVSLJ-UHFFFAOYSA-N 0.000 description 1
IPCKNBMIHWBUOB-UHFFFAOYSA-N 6-[2-[4-(5,6,7,8-tetrahydronaphthalen-1-yl)piperazin-1-yl]ethyl]-3h-1,3-benzoxazol-2-one Chemical compound C1CCCC2=C1C=CC=C2N(CC1)CCN1CCC1=CC=C2NC(=O)OC2=C1 IPCKNBMIHWBUOB-UHFFFAOYSA-N 0.000 description 1
DFQBINVRYBRGFZ-UHFFFAOYSA-N 6-[2-[4-(6-hydroxyquinolin-8-yl)piperazin-1-yl]ethyl]-3h-1,3-benzoxazol-2-one Chemical compound N1=CC=CC2=CC(O)=CC(N3CCN(CCC=4C=C5OC(=O)NC5=CC=4)CC3)=C21 DFQBINVRYBRGFZ-UHFFFAOYSA-N 0.000 description 1
ZOOOZSQMGJVIIH-UHFFFAOYSA-N 6-[4-(4-naphthalen-1-ylpiperazin-1-yl)butyl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCC3=CC=C4NC(OC4=C3)=O)=CC=CC2=C1 ZOOOZSQMGJVIIH-UHFFFAOYSA-N 0.000 description 1
ZTQQXEPZEYIVDK-UHFFFAOYSA-N 6-chloro-5-(2-chloroethyl)-1,3-dihydroindol-2-one Chemical compound C1=C(Cl)C(CCCl)=CC2=C1NC(=O)C2 ZTQQXEPZEYIVDK-UHFFFAOYSA-N 0.000 description 1
PYIOIVVNDDWUBF-UHFFFAOYSA-N 6-fluoro-3,3-dimethyl-1h-indol-2-one Chemical compound FC1=CC=C2C(C)(C)C(=O)NC2=C1 PYIOIVVNDDWUBF-UHFFFAOYSA-N 0.000 description 1
GSSFATVYFHRGQZ-UHFFFAOYSA-N 6-fluoro-5-[2-(4-naphthalen-1-ylpiperazin-1-yl)ethyl]-1,3-dihydroindol-2-one;hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3F)=CC=CC2=C1 GSSFATVYFHRGQZ-UHFFFAOYSA-N 0.000 description 1
WNCJNGKFHAUUFK-UHFFFAOYSA-N 7-fluoro-5-[2-(4-naphthalen-1-ylpiperazin-1-yl)ethyl]-1,3-dihydroindol-2-one;hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC=3C=C(C=4NC(=O)CC=4C=3)F)=CC=CC2=C1 WNCJNGKFHAUUFK-UHFFFAOYSA-N 0.000 description 1
ULPZONMXSOOPJO-UHFFFAOYSA-N 8-piperazin-1-ylquinolin-6-ol Chemical compound C=12N=CC=CC2=CC(O)=CC=1N1CCNCC1 ULPZONMXSOOPJO-UHFFFAOYSA-N 0.000 description 1
DCUZDOXGNVJQQL-UHFFFAOYSA-N 8-piperazin-1-ylquinoline Chemical compound C1CNCCN1C1=CC=CC2=CC=CN=C12 DCUZDOXGNVJQQL-UHFFFAOYSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
WEYRRZDXGAGMSW-UHFFFAOYSA-N Cl.C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C(C4=C3)(C)C)=NSC2=C1 Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C(C4=C3)(C)C)=NSC2=C1 WEYRRZDXGAGMSW-UHFFFAOYSA-N 0.000 description 1
206010014557 Emotional poverty Diseases 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
206010041243 Social avoidant behaviour Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
229960004046 apomorphine Drugs 0.000 description 1
229960003990 apomorphine hydrochloride Drugs 0.000 description 1
150000001502 aryl halides Chemical class 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
AZRWNJFEUSHORT-UHFFFAOYSA-N benzyl-bis(2-chloroethyl)azanium;chloride Chemical compound [Cl-].ClCC[NH+](CCCl)CC1=CC=CC=C1 AZRWNJFEUSHORT-UHFFFAOYSA-N 0.000 description 1
238000009835 boiling Methods 0.000 description 1
125000005997 bromomethyl group Chemical group 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical compound ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
MSQACBWWAIBWIC-UHFFFAOYSA-N hydron;piperazine;chloride Chemical compound Cl.C1CNCCN1 MSQACBWWAIBWIC-UHFFFAOYSA-N 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
229960002868 mechlorethamine hydrochloride Drugs 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
150000005623 oxindoles Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
230000004044 response Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000012265 solid product Substances 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
239000003826 tablet Substances 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Anesthesiology (AREA)
Psychiatry (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Indole Compounds (AREA)

DD88313286A 1987-03-02 1988-03-01 Verfahren zur herstellung von piperazinyl-heterocyclischen verbindungen DD272077A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US8700423		1987-03-02

Publications (1)

Publication Number	Publication Date
DD272077A5 true DD272077A5 (de)	1989-09-27

Family

ID=22202301

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD88313286A DD272077A5 (de)	1987-03-02	1988-03-01	Verfahren zur herstellung von piperazinyl-heterocyclischen verbindungen

Country Status (31)

Country	Link
EP (1)	EP0281309B1 (fr)
JP (1)	JPH0710837B2 (fr)
KR (1)	KR900003492B1 (fr)
CN (1)	CN1015057B (fr)
AR (1)	AR244673A1 (fr)
AT (1)	ATE70833T1 (fr)
AU (1)	AU583762B2 (fr)
BA (1)	BA98296A (fr)
CA (1)	CA1300139C (fr)
CZ (1)	CZ281257B6 (fr)
DD (1)	DD272077A5 (fr)
DE (3)	DE10299021I1 (fr)
DK (1)	DK173065B1 (fr)
EG (1)	EG18398A (fr)
ES (1)	ES2040838T3 (fr)
FI (1)	FI91868C (fr)
GR (1)	GR3003459T3 (fr)
HU (1)	HU207860B (fr)
IE (1)	IE60849B1 (fr)
IL (1)	IL85495A (fr)
LU (1)	LU90944I2 (fr)
MX (1)	MX173362B (fr)
MY (1)	MY103352A (fr)
NO (2)	NO170977C (fr)
NZ (1)	NZ223694A (fr)
PH (1)	PH24119A (fr)
PL (1)	PL157897B1 (fr)
PT (1)	PT86866B (fr)
SU (1)	SU1644716A3 (fr)
YU (1)	YU46639B (fr)
ZA (1)	ZA881447B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60130573A (ja) *	1983-12-15	1985-07-12	Otsuka Pharmaceut Co Ltd	ベンゾチアゾ−ル誘導体
US4720297A (en) *	1985-09-27	1988-01-19	Sumitomo Chemical Company, Limited	Benzothiazolones, and their production and use as herbicides
US4883795A (en) *	1988-01-22	1989-11-28	Pfizer Inc.	Piperazinyl-heterocyclic compounds
FR2631625B1 (fr) *	1988-05-17	1992-10-16	Synthelabo	Derives de phenyl-6 piperazinylalkyl-3 1h,3h-pyrimidinedione-2,4, leur preparation et leur application en therapeutique
US4957916A (en) *	1988-08-05	1990-09-18	Janssen Pharmaceutica N.V.	Antipsychotic 3-piperazinylbenzazole derivatives
US5015740A (en) *	1988-08-05	1991-05-14	Janssen Pharmaceutica N.V.	Antipsychotic 3-piperazinylbenzazole derivatives
HU207310B (en) *	1988-12-02	1993-03-29	Pfizer	Process for producing aryl-piperidine derivatives
WO1991000863A1 (fr) *	1989-07-07	1991-01-24	Pfizer Inc.	Agents antipsychotiques a base de piperazine d'heteroaryle
EP0429341A3 (en) *	1989-11-20	1991-11-13	Rhone-Poulenc Sante	Heterocyclic derivatives, their preparation and pharmaceuticals containing them
FR2655042B1 (fr) *	1989-11-29	1994-01-21	Adir Cie	Nouvelles benzothiazolinones substituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5162324A (en) *	1989-12-20	1992-11-10	Adir Et Compagnie	Naphyl piperazines useful as 5-HT1A receptor ligands
US5166156A (en) *	1989-12-20	1992-11-24	Adir Et Compagnie	Naphthyl piperazines useful as 5-HT1A receptor ligands
FR2655988B1 (fr) *	1989-12-20	1994-05-20	Adir Cie	Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5162321A (en) *	1989-12-20	1992-11-10	Adir Et Compagnie	1-naphthyl piperazines useful as 5-HT1A receptor ligands
US5166157A (en) *	1989-12-20	1992-11-24	Adir Et Compagnie	Naphthyl piperazines useful as 5-HT1A receptor ligands
FR2671350A1 (fr) *	1991-01-08	1992-07-10	Adir	Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant.
US5268381A (en) *	1990-09-26	1993-12-07	Adir Et Compagnie	Aminoalkyl-benzothiazolinone and -benzoxazolinone compounds having a high 5-HT1A affinity
FR2667068B1 (fr) *	1990-09-26	1994-09-09	Adir	Nouvelles amines alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5147881A (en) *	1990-11-14	1992-09-15	Pfizer Inc	4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
US5643784A (en) *	1990-12-04	1997-07-01	H, Lundbeck A/S	Indan derivatives
FR2674524B1 (fr) *	1991-03-25	1993-05-21	Adir	Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
NZ243065A (en)	1991-06-13	1995-07-26	Lundbeck & Co As H	Piperidine derivatives and pharmaceutical compositions
NZ240863A (en) *	1991-09-11	1995-04-27	Mcneilab Inc	Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
DK55192D0 (da) *	1992-04-28	1992-04-28	Lundbeck & Co As H	1-piperazino-1,2-dihydroindenderivater
DK78692D0 (da) *	1992-06-12	1992-06-12	Lundbeck & Co As H	Dimere piperidin- og piperazinderivater
US5206366A (en) *	1992-08-26	1993-04-27	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) *	1992-09-01	1994-05-17	Pfizer Inc.	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
DK148392D0 (da) *	1992-12-09	1992-12-09	Lundbeck & Co As H	Heterocykliske forbindelser
EP0635506A4 (fr) *	1993-02-04	1995-04-12	Meiji Seika Co	Compose a effet neuroleptique.
FR2702214B1 (fr) *	1993-03-05	1995-04-14	Adir	Nouveaux composés (aryl(alkyl)carbonyl)-hétérocycliques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
GB9305623D0 (en) *	1993-03-18	1993-05-05	Merck Sharp & Dohme	Therapeutic agents
ES2083319B1 (es) *	1993-09-20	1997-01-16	Pfizer	Monohidrato de clorhidrato de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil)-6-cloro-1,3-dihidro-2h-indol-2-ona.
FR2717807B1 (fr) *	1994-03-22	1996-04-19	Adir	Nouvelles 6- [(4-arylalkyl-1-piperazino)alkyl] benzothiazolinones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
FI951296A7 (fi) *	1994-03-22	1995-09-23	Servier Lab	Uudet aminoalkyylibentsotiatsolinonit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
JP3274579B2 (ja) *	1995-01-12	2002-04-15	住友製薬株式会社	脳血管障害に伴う精神症候治療剤
IL118768A (en) *	1995-07-12	2000-10-31	Akzo Nobel Nv	Diphenylmethane piperidine derivatives pharmaceutical compositions containing them and a method for their preparation
US6187774B1 (en) *	1996-03-04	2001-02-13	Yoshitomi Pharmaceutical Industries, Ltd.	Fused heterocyclic compounds and pharmaceutical applications thereof
TR199802241T2 (fr) *	1996-05-07	1999-02-22	Pfizer Inc.
UA57734C2 (uk)	1996-05-07	2003-07-15	Пфайзер Інк.	Комплекси включення арилгетероциклічних солей
TW491847B (en)	1996-05-07	2002-06-21	Pfizer	Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
FR2755690B1 (fr) *	1996-11-08	1998-12-18	Adir	Nouveaux derives aminomethyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6150366A (en) *	1998-06-15	2000-11-21	Pfizer Inc.	Ziprasidone formulations
AR030357A1 (es) *	2000-08-18	2003-08-20	Lundbeck & Co As H	Derivados 4 -, 5 -, 6 - y 7-indol
US7504395B2 (en)	2001-07-20	2009-03-17	Psychogenics, Inc.	Treatment for attention-deficit hyperactivity disorder
US20060089400A1 (en) *	2002-05-03	2006-04-27	The Vernalis Group Of Companies	Novel spiro ketone and carboxylic acid derivatives as specific inhibitors for (po3h2) ser/(po3h2)thr-pro-specific peptidyl-prolylcis/trans-isomerases
CA2498215A1 (fr) *	2002-10-28	2004-05-06	Warner-Lambert Company Llc	Derives de piperazine substitues par un oxindole
JP2007502856A (ja) *	2003-05-16	2007-02-15	ファイザー・プロダクツ・インク	精神病性障害および抑うつ性障害の治療
EP1626722A1 (fr) *	2003-05-16	2006-02-22	Pfizer Products Inc.	Procede pour ameliorer les fonctions cognitives en administrant du ziprasidone
BRPI0410419A (pt) *	2003-05-16	2006-05-30	Pfizer Prod Inc	tratamento para a ansiedade com ziprasidona
HRP20090054T3 (hr) *	2004-05-11	2009-03-31	EGIS Gy�gyszergy�r Nyrt	Derivati piperazina alkilnih oksindola
HUP0400953A3 (en)	2004-05-11	2008-02-28	Egis Gyogyszergyar Nyilvanosan	Piperazine derivatives of alkyl-oxindoles, pharmaceutical compositions containing them, process for producing them and their use
WO2006011157A2 (fr) *	2004-06-18	2006-02-02	Lupin Limited	Nouveau procede de preparation de composes heterocycliques aryle-piperazinyle
ES2250000B1 (es) *	2004-09-29	2007-06-01	Medichem, S.A.	Procedimiento para la preparacion de ziprasidona.
JO2769B1 (en)	2005-10-26	2014-03-15	جانسين فارماسوتيكا ان. في	Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
HUP0600868A3 (en) *	2006-11-24	2009-03-30	Richter Gedeon Nyrt	5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one hydrogen bromide polimorphs and process for their preparation
JO2642B1 (en)	2006-12-08	2012-06-17	جانسين فارماسوتيكا ان. في	Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en)	2007-02-13	2015-03-15	جانسين فارماسوتيكا ان. في	Dopamine 2 receptor antagonists are rapidly hydrolyzed
JP5431305B2 (ja)	2007-04-23	2014-03-05	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	高速解離性ドパミン２受容体アンタゴニストとしての４−アルコキシピリダジン誘導体
RU2489431C2 (ru)	2007-04-23	2013-08-10	Янссен Фармацевтика Н.В.	Тиа(диа)золы как быстро диссоциирующие антагонисты рецептора допамина 2
JP5417439B2 (ja)	2008-07-03	2014-02-12	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	５−ｈｔ６受容体アンタゴニストとしての置換された６−（１−ピペラジニル）−ピリダジン類
EA019048B1 (ru)	2008-07-31	2013-12-30	Янссен Фармацевтика Нв	Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d-рецепторов дофамина
PT2445502T (pt) *	2009-06-25	2017-09-22	Alkermes Pharma Ireland Ltd	Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
PL391810A1 (pl)	2010-07-14	2012-01-16	Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna	Nowe sole ziprasidonu oraz sposoby ich otrzymywania
SI23610A (sl)	2011-01-13	2012-07-31	Diagen@d@o@o	Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
US10154988B2 (en)	2012-11-14	2018-12-18	The Johns Hopkins University	Methods and compositions for treating schizophrenia
MA41169A (fr) *	2014-12-17	2017-10-24	Acraf	Composés antibactériens à large spectre d'activité
AU2019230014B2 (en)	2018-03-05	2024-11-28	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy
CN117820309B (zh) *	2022-09-28	2026-07-14	江苏恩华药业股份有限公司	一种哌嗪基-杂环化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179505A (en) *	1977-03-30	1979-12-18	Janssen Pharmaceutica N.V.	5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives
FR2536749A1 (fr) *	1982-11-25	1984-06-01	Cerm Cent Europ Rech Mauvernay	(amino-2 ethyl)-6 benzoxazolinones substituees, leur preparation et leurs applications en therapeutique
US4554284A (en) *	1984-09-12	1985-11-19	Smithkline Beckman Corporation	7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones
JPH0625181B2 (ja) *	1985-03-27	1994-04-06	住友製薬株式会社	新規なイミド誘導体
NL8601494A (nl) *	1985-06-22	1987-01-16	Sandoz Ag	Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten.
JPS6212768A (ja) *	1985-06-22	1987-01-21	サンド・アクチエンゲゼルシヤフト	新規チアゾ−ル類、その製法および医薬
MX174210B (es) *	1987-02-17	1994-04-28	Pfizer	Procedimiento para la preparacion de compuestos arilpiperazinil-alquilenfenil-p-heterociclicos

1987
- 1987-03-02 MX MX1062188A patent/MX173362B/es unknown
1988
- 1988-02-22 IL IL85495A patent/IL85495A/xx not_active IP Right Cessation
- 1988-02-24 ES ES198888301561T patent/ES2040838T3/es not_active Expired - Lifetime
- 1988-02-24 EP EP88301561A patent/EP0281309B1/fr not_active Expired - Lifetime
- 1988-02-24 DE DE2002199021 patent/DE10299021I1/de active Pending
- 1988-02-24 DE DE19883867089 patent/DE10299021I2/de active Active
- 1988-02-24 DE DE8888301561T patent/DE3867089D1/de not_active Expired - Lifetime
- 1988-02-24 AT AT88301561T patent/ATE70833T1/de active
- 1988-02-29 PT PT86866A patent/PT86866B/pt active IP Right Grant
- 1988-02-29 CA CA000560086A patent/CA1300139C/fr not_active Expired - Lifetime
- 1988-03-01 DD DD88313286A patent/DD272077A5/de unknown
- 1988-03-01 PH PH36572A patent/PH24119A/en unknown
- 1988-03-01 AR AR88310191A patent/AR244673A1/es active
- 1988-03-01 YU YU40688A patent/YU46639B/sh unknown
- 1988-03-01 DK DK198801083A patent/DK173065B1/da not_active IP Right Cessation
- 1988-03-01 FI FI880941A patent/FI91868C/fi not_active IP Right Cessation
- 1988-03-01 MY MYPI88000206A patent/MY103352A/en unknown
- 1988-03-01 PL PL1988270925A patent/PL157897B1/pl unknown
- 1988-03-01 AU AU12537/88A patent/AU583762B2/en not_active Expired
- 1988-03-01 NZ NZ223694A patent/NZ223694A/xx unknown
- 1988-03-01 SU SU884355508A patent/SU1644716A3/ru active
- 1988-03-01 HU HU88976A patent/HU207860B/hu unknown
- 1988-03-01 CZ CS881317A patent/CZ281257B6/cs not_active IP Right Cessation
- 1988-03-01 NO NO880901A patent/NO170977C/no not_active IP Right Cessation
- 1988-03-01 EG EG115/88A patent/EG18398A/xx active
- 1988-03-01 IE IE57488A patent/IE60849B1/en not_active IP Right Cessation
- 1988-03-01 CN CN88101642A patent/CN1015057B/zh not_active Expired
- 1988-03-01 ZA ZA881447A patent/ZA881447B/xx unknown
- 1988-03-02 KR KR1019880002163A patent/KR900003492B1/ko not_active Expired
- 1988-03-02 JP JP4945288A patent/JPH0710837B2/ja not_active Expired - Lifetime
1991
- 1991-12-30 GR GR91402162T patent/GR3003459T3/el unknown
1998
- 1998-03-30 BA BA980296A patent/BA98296A/bs unknown
2002
- 2002-05-28 NO NO2002004C patent/NO2002004I2/no unknown
- 2002-08-07 LU LU90944C patent/LU90944I2/fr unknown

Also Published As

Publication number	Publication date
AR244673A1 (es)	1993-11-30
BA98296A (bs)	2001-09-14
NZ223694A (en)	1990-02-26
IL85495A0 (en)	1988-07-31
JPH0710837B2 (ja)	1995-02-08
EP0281309B1 (fr)	1991-12-27
CA1300139C (fr)	1992-05-05
MX173362B (es)	1994-02-23
KR900003492B1 (ko)	1990-05-21
DE10299021I2 (de)	2007-05-10
PT86866A (pt)	1988-03-01
ZA881447B (en)	1989-10-25
IL85495A (en)	1993-05-13
CZ281257B6 (cs)	1996-07-17
IE60849B1 (en)	1994-08-24
DK108388A (da)	1988-09-03
SU1644716A3 (ru)	1991-04-23
NO170977B (no)	1992-09-28
JPS63301861A (ja)	1988-12-08
NO2002004I2 (no)	2007-02-12
ES2040838T3 (es)	1993-11-01
FI91868B (fi)	1994-05-13
NO170977C (no)	1993-01-06
PH24119A (en)	1990-03-05
PL157897B1 (pl)	1992-07-31
PT86866B (pt)	1992-05-29
FI880941A0 (fi)	1988-03-01
EP0281309A1 (fr)	1988-09-07
HU207860B (en)	1993-06-28
DK173065B1 (da)	1999-12-13
YU40688A (en)	1989-12-31
AU583762B2 (en)	1989-05-04
NO880901D0 (no)	1988-03-01
DK108388D0 (da)	1988-03-01
YU46639B (sh)	1994-01-20
EG18398A (en)	1993-02-28
FI91868C (fi)	1994-08-25
DE10299021I1 (de)	2002-09-26
HUT50330A (en)	1990-01-29
AU1253788A (en)	1988-09-01
KR880011142A (ko)	1988-10-26
PL270925A1 (en)	1988-12-08
IE880574L (en)	1988-09-02
NO880901L (no)	1988-09-05
CZ131788A3 (en)	1996-05-15
DE3867089D1 (de)	1992-02-06
CN1015057B (zh)	1991-12-11
GR3003459T3 (en)	1993-02-17
MX10621A (es)	1993-09-01
ATE70833T1 (de)	1992-01-15
LU90944I2 (fr)	2002-10-07
MY103352A (en)	1993-06-30
FI880941A7 (fi)	1988-09-03
CN88101642A (zh)	1988-09-14

Legal Events

Date	Code	Title	Description
1994-04-14	NPV	Change in the person, the name or the address of the representative (addendum to changes before extension act)
2004-04-28	IF04	In force in the year 2004	Expiry date: 20080302

Publication	Publication Date	Title
EP0281309B1 (fr)	1991-12-27	Dérivés pipérazinyl-hétérocycliques
DE69810889T2 (de)	2003-05-15	Heterozyklische Piperazinyl Verbindungen zur Behandlung von Demenz
US4831031A (en)	1989-05-16	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en)	1989-11-28	Piperazinyl-heterocyclic compounds
DE69013836T2 (de)	1995-03-23	Benzimidazolverbindungen und deren Anwendung.
DE69013601T2 (de)	1995-03-02	Heteroaryl Piperazine als antipsychotische Mittel.
DE69128231T2 (de)	1998-06-18	Heterozyklische Alkylamine, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten
DE69434020T2 (de)	2005-09-29	Verfahren und zwischenprodukte für die herstellung von 5-[4-(benzisothiazol-3-yl)-piperazin-1-yl)ethyl]-6 chlor-1,3-dihydro-indol-2-one
DE2309160A1 (de)	1973-09-27	2-imidazolin-2-yl-amino-substituierte, benzokondensierte, heterocyclische verbindungen und arzneipraeparate
EP0006506B1 (fr)	1981-09-16	Dérivés de la dihydro-1.2-oxo-2-quinoléine, procédés pour leur préparation et médicaments les contenant
EP0129128A2 (fr)	1984-12-27	Dérivés de 2-pyrimidinyl 1-pipérazine, procédé pour leur préparation et médicaments les contenant
JPH06502639A (ja)	1994-03-24	特定のイミダゾキノキサリン；新種のｇａｂａ脳受容体リガンド
DE4031287A1 (de)	1992-04-09	Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JP2006528236A (ja)	2006-12-14	ジプラシドンを用いて認知を増強する方法
JPS5879983A (ja)	1983-05-13	新規なベンズイミダゾ−ル誘導体、その製造法およびその医薬組成物
DE3884007T2 (de)	1994-01-20	Arylpiperazinylalkylenphenylheterocyclische Verbindungen.
CH622793A5 (fr)	1981-04-30
DE69836783T2 (de)	2007-10-31	Methode zur Behandlung des Tourette-Syndroms
DE60202969T2 (de)	2006-01-19	Substituierte alkylaminopyridazinonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
US5096900A (en)	1992-03-17	(4-piperidyl)methyl-2,3-dihydro-1h-isoindole and -2,3,4,5-tetrahydro-1h-benzazepine derivatives, their preparation and their application in therapy
DE2051962A1 (de)	1971-04-29	Benzimidazo eckige Klammer auf l,2d eckige Klammer zu eckige Klammer auf 1,4 eckige Klammer zu benzodiazepin 6 (5H) one und Verfahren zu deren Her stellung
DE69910706T2 (de)	2004-07-08	Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie
US5081128A (en)	1992-01-14	2,3-dihydro-1h-isoindole derivatives and their application in therapy
WO1999020616A1 (fr)	1999-04-29	Derives de 1,2-benzisothiazol 2-substitues, leur preparation et leur utilisation comme antagonistes de la serotonine (5-ht1a, 5-ht1b et 5-ht1d)
DE3248094C1 (de)	1984-06-14	7H-Dibenzo(a,c)cyclohepten-5-on(7)-Derivate,Verfahren zu deren Herstellung und deren Verwendung bei der Bekaempfung psychischer Erkrankungen und von Magen-und/oder Darmgeschwueren